Artelo Biosciences (Artelo Biosciences) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Change In Receivables?

Artelo Biosciences's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Artelo Biosciences's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Artelo Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Artelo Biosciences's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Artelo Biosciences's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Artelo Biosciences's liquidation value for the three months ended in Mar. 2024 was $6.79 Mil.

Artelo Biosciences Change In Receivables Historical Data

The historical data trend for Artelo Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Change In Receivables Chart

Artelo Biosciences Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.01

Artelo Biosciences Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Artelo Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Artelo Biosciences (NAS:ARTLW) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Artelo Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Artelo Biosciences's accounts receivable are only considered to be worth 75% of book value:

Artelo Biosciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7.609	-	0.817	+	0.75 * 0	+	0.5 * 0
=	6.79

Artelo Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences (Artelo Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ARTL:USA

Address

505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075

Website

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.